Wanda Panosh, MD
Internal Medicine · Greensboro, NCNPI 1992761993
Payments from drug & device makers
Across 145 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$534
- Lilly USA, LLC$239
- Amgen$202
- Boehringer Ingelheim$195
- Dexcom, Inc.$169
- Abbott$144
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $534 |
| Lilly USA, LLC | 14 | $239 |
| Amgen | 13 | $202 |
| Boehringer Ingelheim | 12 | $195 |
| Dexcom, Inc. | 6 | $169 |
| Abbott | 6 | $144 |
| Biohaven Pharmaceuticals, Inc. | 7 | $142 |
| Otsuka America Pharmaceutical, Inc. | 5 | $127 |
| Amarin Pharma, Inc. | 6 | $78 |
| Pfizer | 5 | $65 |
| Merck | 5 | $64 |
| Dynavax Technologies Corporation | 3 | $51 |
| Medtronic | 1 | $47 |
| Irhythm Technologies, Inc. | 1 | $44 |
| Lundbeck LLC | 2 | $40 |
| C2n Diagnostics, LLC | 1 | $37 |
| Exact Sciences | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Sanofi | 1 | $31 |
| AstraZeneca | 2 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Corcept Therapeutics | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Corium, LLC | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| GSK | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Edwards Lifesciences | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $13 |
| Gilead | 1 | $11 |
How this compares
$2,579 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $41,131 |
| OzempicSemaglutide | 38 | $35,780 |
| FarxigaDapagliflozin Propanediol | 32 | $22,838 |
| JardianceEmpagliflozin | 18 | $13,585 |
| RybelsusSemaglutide | 13 | $12,261 |
| EliquisApixaban | 12 | $8,130 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 13 | $3,056 |
| SynthroidLevothyroxine Sodium | 20 | $2,285 |
| Levothyroxine Sodium | 162 | $1,668 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,402 |
| Atorvastatin Calcium | 160 | $1,369 |
| ValacyclovirValacyclovir Hcl | 20 | $1,295 |
| Losartan Potassium | 119 | $1,190 |
| Rosuvastatin Calcium | 99 | $1,111 |
| Valsartan | 24 | $1,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $534 | $48,04251 claims |
| Lilly USA, LLCMounjaro | $239 | $41,13132 claims |
| AstraZenecaFarxiga | $29 | $22,83832 claims |
| Boehringer IngelheimJardiance | $195 | $13,58518 claims |
| PfizerEliquis | $65 | $8,13012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Greensboro
- Keung LeeGreensboro$5.1M
- Walter PharrGreensboro$2.3M
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.